Long Read Sequencing Market Dynamics Shaping the Future of Personalized Healthcare :

Read More: https://www.theinsightpartners.....com/reports/long-re

The long read sequencing market was valued at US$ 1,101.15 million in 2020 and it is projected to reach US$ 5,334.68 million by 2028; it is expected to grow at a CAGR of 22.3% during 2021–2028.  The long read sequencing is a DNA sequencing technique. It offers numerous distinct advantages than next-generation sequencing technologies such as more precisely sequence DNA containing the same sections of DNA repeated within the genome. Many adults aged 60 years and above suffer from two or more chronic illnesses. Genes play a role in chronic diseases such as cardiovascular disease, diabetes, obesity, RA, Alzheimer's disease (AD), and depression, according to twin research. According to the Centers for Disease Control and Prevention (CDC), about 6 out of 10 individuals in the US are affected by at least one chronic disease, as well as 4 out of 10 are suffering from two or more chronic diseases.

Furthermore, cancer is primarily caused by genomic errors. Researchers have analyzed cancer genomes using a variety of rapidly evolving sequencing technologies in order to better understand cancer cells' molecular status and expose their vulnerabilities such as driver mutations or gene expression. The researchers were able to recognize and classify new forms of cancerous mutations using long-read technologies, including complex structural variants in haplotype resolution. In recent years, several long read sequencing technologies have been developed and used. For example, Pacific Biosciences developed SMRT sequencing, which is one of the long read methods (PacBio). Long read sequencing is becoming more common, and cancer studies based on long read data are growing and advancing in order to decode complex cancer genomes.